{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T13:09:25Z","timestamp":1776172165903,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["428212161"],"award-info":[{"award-number":["428212161"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ejca.2026.116690","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T17:48:30Z","timestamp":1773942510000},"page":"116690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Multi-modal computational data analysis for prediction of response to systemic treatment in metastatic melanoma"],"prefix":"10.1016","volume":"238","author":[{"given":"Vicky","family":"Parmar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6930-2694","authenticated-orcid":false,"given":"Georg","family":"Lodde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Haubold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1760-2342","authenticated-orcid":false,"given":"Ren\u00e9","family":"Hosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Borys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5811-7100","authenticated-orcid":false,"given":"Felix","family":"Nensa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michal-Kamil","family":"Chodyla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0719-2207","authenticated-orcid":false,"given":"Mathias","family":"Holtkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Forsting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3524-7858","authenticated-orcid":false,"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3680-3521","authenticated-orcid":false,"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8279-9239","authenticated-orcid":false,"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5215-7171","authenticated-orcid":false,"given":"Lale","family":"Umutlu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.116690_bib1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.116690_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41572-025-00603-8","article-title":"Cutaneous melanoma","volume":"11","author":"Tasdogan","year":"2025","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.ejca.2026.116690_bib3","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.2007.12.7837","article-title":"Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials","volume":"26","author":"Korn","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116690_bib4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116690_bib5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116690_bib6","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116690_bib7","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116690_bib8","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116690_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.116690_bib10","doi-asserted-by":"crossref","first-page":"78174","DOI":"10.18632\/oncotarget.19836","article-title":"BRAF inhibitors: resistance and the promise of combination treatments for melanoma","volume":"8","author":"Griffin","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2026.116690_bib11","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2147\/OTT.S39096","article-title":"BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies","volume":"8","author":"Spagnolo","year":"2015","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.ejca.2026.116690_bib12","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1038\/s41467-020-19075-3","article-title":"Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1\/2-mediated reactivation of MEK\/ERK\/MYC signaling","volume":"11","author":"Tripathi","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2026.116690_bib13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1148\/radiol.2015151169","article-title":"Radiomics: images are more than pictures, they are data","volume":"278","author":"Gillies","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.ejca.2026.116690_bib14","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/annonc\/mdx034","article-title":"Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology","volume":"28","author":"Limkin","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.116690_bib15","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1148\/rg.2021210037","article-title":"Radiomics in oncology: a practical guide","volume":"41","author":"Shur","year":"2021","journal-title":"Radiographics"},{"key":"10.1016\/j.ejca.2026.116690_bib16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2026.116690_bib17","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s11548-022-02662-8","article-title":"Metastatic melanoma treated by immunotherapy: discovering prognostic markers from radiomics analysis of pretreatment CT with feature selection and classification","volume":"17","author":"Ungan","year":"2022","journal-title":"Int J Comput Assist Radiol Surg"},{"key":"10.1016\/j.ejca.2026.116690_bib18","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3389\/fonc.2020.01524","article-title":"Pilot study of CT-based radiomics model for early evaluation of response to immunotherapy in patients with metastatic melanoma","volume":"10","author":"Wang","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2026.116690_bib19","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1158\/1541-7786.MCR-20-1038","article-title":"Radiomics biomarkers correlate with CD8 expression and predict immune signatures in melanoma patients","volume":"19","author":"Aoude","year":"2021","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ejca.2026.116690_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics12040929","article-title":"The role and potential of (18)F-FDG PET\/CT in malignant melanoma: prognostication, monitoring response to targeted and immunotherapy, and radiomics","volume":"12","author":"Filippi","year":"2022","journal-title":"Diagnostics"},{"key":"10.1016\/j.ejca.2026.116690_bib21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejca.2023.02.017","article-title":"CT radiomics compared to a clinical model for predicting checkpoint inhibitor treatment outcomes in patients with advanced melanoma","volume":"185","author":"Ter Maat","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.116690_bib22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/jamaoncol.2021.6818","article-title":"Early readout on overall survival of patients with melanoma treated with immunotherapy using a novel imaging analysis","volume":"8","author":"Dercle","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2026.116690_bib23","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","article-title":"Predictive biomarkers for checkpoint inhibitor-based immunotherapy","volume":"17","author":"Gibney","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2026.116690_bib24","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejca.2026.116690_bib25","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1038\/ncomms6694","article-title":"Increased MAPK reactivation in early resistance to dabrafenib\/trametinib combination therapy of BRAF-mutant metastatic melanoma","volume":"5","author":"Long","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2026.116690_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22083837","article-title":"Precision medicine and melanoma: multi-omics approaches to monitoring the immunotherapy response","volume":"22","author":"Valenti","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejca.2026.116690_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2019.108688","article-title":"Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy","volume":"121","author":"Schraag","year":"2019","journal-title":"Eur J Radio"},{"key":"10.1016\/j.ejca.2026.116690_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13203210","article-title":"Can whole-body baseline CT radiomics add information to the prediction of best response, progression-free survival, and overall survival of stage iv melanoma patients receiving first-line targeted therapy: a retrospective register study","volume":"13","author":"Peisen","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.ejca.2026.116690_bib29","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1158\/1078-0432.CCR-20-0020","article-title":"Radiomics, tumor volume, and blood biomarkers for early prediction of pseudoprogression in patients with metastatic melanoma treated with immune checkpoint inhibition","volume":"26","author":"Basler","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2026.116690_bib30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/RLI.0000000000001040","article-title":"BOA: a CT-based body and organ analysis for radiologists at the point of care","volume":"59","author":"Haubold","year":"2024","journal-title":"Invest Radio"},{"key":"10.1016\/j.ejca.2026.116690_bib31","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41746-025-02016-z","article-title":"Leveraging Sarcopenia index by automated CT body composition analysis for pan cancer prognostic stratification","volume":"8","author":"Borys","year":"2025","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.ejca.2026.116690_bib32","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1186\/s12967-025-06507-1","article-title":"Fully volumetric body composition analysis for prognostic overall survival stratification in melanoma patients","volume":"23","author":"Borys","year":"2025","journal-title":"J Transl Med"},{"key":"10.1016\/j.ejca.2026.116690_bib33","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1158\/0008-5472.CAN-17-0339","article-title":"Computational radiomics system to decode the radiographic phenotype","volume":"77","author":"van Griethuysen","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2026.116690_bib34","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1145\/2939672.2939785","article-title":"XGBoost: A Scalable Tree Boosting System","author":"Chen","year":"2016","journal-title":"Proc 22nd ACM SIGKDD Int Conf Knowl Discov Data Min"},{"key":"10.1016\/j.ejca.2026.116690_bib35","first-page":"2623","article-title":"Optuna: A Next-generation Hyperparameter Optimization Framework","author":"Akiba","year":"2019","journal-title":"Proc 25th ACM SIGKDD Int Conf Knowl Discov & Data Min"},{"key":"10.1016\/j.ejca.2026.116690_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14122992","article-title":"Combination of whole-body baseline ct radiomics and clinical parameters to predict response and survival in a stage-iv melanoma cohort undergoing immunotherapy","volume":"14","author":"Peisen","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2026.116690_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009568","article-title":"Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma","volume":"13","author":"Tompkins","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2026.116690_bib38","doi-asserted-by":"crossref","DOI":"10.1002\/acm2.14192","article-title":"Investigating the role of imaging factors in the variability of CT-based texture analysis metrics","volume":"25","author":"Varghese","year":"2024","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.ejca.2026.116690_bib39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cncr.32522","article-title":"Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy","volume":"126","author":"Pires da Silva","year":"2020","journal-title":"Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926004703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926004703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:32:39Z","timestamp":1776169959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926004703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":39,"alternative-id":["S0959804926004703"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116690","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multi-modal computational data analysis for prediction of response to systemic treatment in metastatic melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.116690","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"116690"}}